No conviction changes recorded
Upgrade to premium to see the full reasoning behind each conviction change.
Sign in to unlockFair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
16.3%/yr
±3.9% · revenue growth to justify current price
FCF-Based Reverse DCF
13.8%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockNo analysis yet
No analysis yet
Q1 FY2026 record: $669M sales (+9%), ATS segment +20% organic driven by semiconductor capex. AI computing driving dispense and x-ray demand. fPE 21.8x fair but not cheap. 16% analyst upside to $312. C...
NDSN Q1: ATS accelerating 20.7% organic in semiconductor/electronics dispense. IPS margins pressured by mix. Strong operating leverage and cash generation. Riding AI/semi capex cycle. Valuation: 31x T...